Literature DB >> 8898817

Serum neuron-specific enolase, carnosinase, and their ratio in acute stroke. An enzymatic test for predicting outcome?

R J Butterworth1, W S Wassif, R A Sherwood, A Gerges, K H Poyser, J Garthwaite, T J Peters, P M Bath.   

Abstract

BACKGROUND AND
PURPOSE: Few admission variables adequately predict neuronal damage and prognosis in individual patients after stroke. Therefore, there is a need for a reliable non-invasive surrogate measure of clinical outcome.
METHODS: We have developed a surrogate measure of stroke outcome using the ratio of serum neuron-specific enolase (NSE) to human serum carnosinase (HSC) in 124 patients with acute ischemic or hemorrhagic stroke and 61 matched control subjects. Serum NSE is known to rise and HSC to fall after neuronal injury such as cerebral ischemia.
RESULTS: Serum NSE levels were significantly higher and HSC levels lower in the patient group. The NSE/HSC ratio was elevated in patients with stroke: median (semiquartile) hemorrhages, 0.072 (0.033); infarcts, 0.039 (0.026); and control subjects, 0.019 (0.014), P = .0001. Patients with a primary intracerebral hemorrhage had nonsignificantly higher ratios than those with an infarct (P = .082). The NSE/HSC ratio was significantly associated with 90-day outcome measured in two out of three disability and handicap scales: modified Barthel Index (rs = -.34, P = .001), modified Rankin Scale (rs = .30, P = .002), and Lindley Score (rs = .19, P = .057). Patients who died or were institutionalized had higher ratios than those who were discharged home: 0.069 (0.043) versus 0.038 (0.024), P = .011. Correlations between the NSE/HSC ratio and outcome were comparable to those between patient age or consciousness level on admission and clinical outcome.
CONCLUSIONS: We believe that measurement of NSE, HSC, or their ratio may be useful in the assessment of patients with acute stroke with respect to diagnosis and prediction of clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898817     DOI: 10.1161/01.str.27.11.2064

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Correlation of Brain Biomarker Neuron Specific Enolase (NSE) with Degree of Disability and Neurological Worsening in Cerebrovascular Stroke.

Authors:  Anuradha Bharosay; Vivek Vikram Bharosay; Meena Varma; Kiran Saxena; Ajoy Sodani; Ravi Saxena
Journal:  Indian J Clin Biochem       Date:  2011-11-08

2.  Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia.

Authors:  K J Becker; R M McCarron; C Ruetzler; O Laban; E Sternberg; K C Flanders; J M Hallenbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

3.  Failure of intraoperative jugular bulb S-100B and neuron-specific enolase sampling to predict cognitive injury after carotid endarterectomy.

Authors:  Daniel H Sahlein; Eric J Heyer; Anita Rampersad; Christopher J Winfree; Robert A Solomon; Alan I Benvenisty; Donald O Quest; Evelyn Du; E Sander Connolly
Journal:  Neurosurgery       Date:  2003-12       Impact factor: 4.654

4.  Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation.

Authors:  Johan Undén; Karin Strandberg; Jan Malm; Eric Campbell; Lars Rosengren; Johan Stenflo; Bo Norrving; Bertil Romner; Arne Lindgren; Gunnar Andsberg
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

5.  Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100.

Authors:  Neil R Grubb; Catriona Simpson; Roy A Sherwood; Hagosa D Abraha; Stuart M Cobbe; Ronan E O'Carroll; Ian Deary; Keith A A Fox
Journal:  Heart       Date:  2007-05-13       Impact factor: 5.994

6.  Correlative study between neuron-specific enolase and blood sugar level in ischemic stroke patients.

Authors:  Aparna Pandey; Kiran Saxena; Meena Verma; Anuradha Bharosay
Journal:  J Neurosci Rural Pract       Date:  2011-01

7.  Primary study for the therapeutic dose and time window of picroside II in treating cerebral ischemic injury in rats.

Authors:  Haitao Pei; Xi Su; Li Zhao; Hongyun Li; Yunliang Guo; Menizeng Zhang; Hui Xin
Journal:  Int J Mol Sci       Date:  2012-02-23       Impact factor: 6.208

8.  Serum and cerebrospinal fluid neuron-specific enolase for diagnosis of tuberculous meningitis.

Authors:  Tae-Jin Song; Young-Chul Choi; Kyung-Yul Lee; Won-Joo Kim
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

9.  Brain type carnosinase in dementia: a pilot study.

Authors:  Cynthia M Balion; Carolyn Benson; Parminder S Raina; Alexandra Papaioannou; Christopher Patterson; Afisi S Ismaila
Journal:  BMC Neurol       Date:  2007-11-05       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.